Compare Crispr Therapeutics AG (CRSP) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Prudential PLC — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $5.23B), while Prudential PLC trades at $27.49 (market cap $34.02B). The key difference: Prudential PLC is far larger — about 6.5× Crispr Therapeutics AG's market cap, and Prudential PLC pays a 1.94% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PUK | |
|---|---|---|
Market Cap | $5.23B | $34.02B |
Sector | Health | Financials |
52-Week High | $76.78 | $33.61 |
52-Week Low | $44.34 | $24.98 |
Enterprise Value | $3.65B | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Prudential PLC (PUK) trades at $27.48, down 2.62% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income of $2.29B, while cash flow from operations surged to $3.61B. Recent news highlights a dividend declaration and strategic acquisitions, but shares face pressure from China regulatory concerns.
The outlook is mixed: attractive valuation and profitability support upside, but bearish technicals and China-related risks pose headwinds. Analyst consensus leans buy (50%), with institutional focus on execution of cost-cutting and geographic strategy. Key risks include regulatory changes in Asia and market volatility impacting near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
